School of Medicine
Showing 1-28 of 28 Results
-
Stephen J. Galli, MD
Mary Hewitt Loveless, MD, Professor in the School of Medicine and Professor of Pathology and of Microbiology and Immunology
Current Research and Scholarly InterestsThe goals of Dr. Galli's laboratory are to understand the regulation of mast cell and basophil development and function, and to develop and use genetic approaches to elucidate the roles of these cells in health and disease. We study both the roles of mast cells, basophils, and IgE in normal physiology and host defense, e.g., in responses to parasites and in enhancing resistance to venoms, and also their roles in pathology, e.g., anaphylaxis, food allergy, and asthma, both in mice and humans.
-
Kristen N Ganjoo
Professor of Medicine (Oncology)
Current Research and Scholarly InterestsGiant cell tumor of the bone
Gastrointestinal stromal tumors
Soft tissue sarcoma
Osteosarcoma -
Xiaojing Gao
Assistant Professor of Chemical Engineering
Current Research and Scholarly InterestsHow do we design biological systems as “smart medicine” that sense patients’ states, process the information, and respond accordingly? To realize this vision, we will tackle fundamental challenges across different levels of complexity, such as (1) protein components that minimize their crosstalk with human cells and immunogenicity, (2) biomolecular circuits that function robustly in different cells and are easy to deliver, (3) multicellular consortia that communicate through scalable channels, and (4) therapeutic modules that interface with physiological inputs/outputs. Our engineering targets include biomolecules, molecular circuits, viruses, and cells, and our approach combines quantitative experimental analysis with computational simulation. The molecular tools we build will be applied to diverse fields such as neurobiology and cancer therapy.
-
Chris Garcia
Younger Family Professor and Professor of Structural Biology
Current Research and Scholarly InterestsStructural and functional studies of transmembrane receptor interactions with their ligands in systems relevant to human health and disease - primarily in immunity, infection, and neurobiology. We study these problems using protein engineering, structural, biochemical, and combinatorial biology approaches.
-
Christopher Gardner
Rehnborg Farquhar Professor
Current Research and Scholarly InterestsThe role of nutrition in individual and societal health, with particular interests in: plant-based diets, differential response to low-carb vs. low-fat weight loss diets by insulin resistance status, chronic disease prevention, randomized controlled trials, human nutrition, community based studies, Community Based Participatory Research, sustainable food movement (animal rights and welfare, global warming, human labor practices), stealth health, nutrition policy, nutrition guidelines
-
Charles Gawad
Associate Professor of Pediatrics (Hematology/Oncology)
BioOur lab works at the interface of biotechnology, computational biology, cellular biology, and clinical medicine to develop and apply new tools for characterizing genetic variation across single cells within a tissue with unparalleled sensitivity and accuracy. We are focused on applying these technologies to study cancer clonal evolution while patients are undergoing treatment with the aim of identifying cancer clonotypes that are associated with resistance to specific drugs so as to better understand and predict treatment response. We are also applying these methods to understand how more virulent pathogens emerge from a population of bacteria or viruses with an emphasis on developing a deeper understanding of how antibiotic resistance develops.
-
Michael Gensheimer
Clinical Associate Professor, Radiation Oncology - Radiation Therapy
Current Research and Scholarly InterestsIn addition to my clinical research in head and neck and lung cancer, I work on the application of computer science and machine learning to cancer research. I develop tools for analyzing large datasets to improve outcomes and safety of cancer treatment. I developed a machine learning prognostic model using data from around 13,000 patients with metastatic cancer which performs better than traditional models and physicians [PubMed ID 33313792]. We recently completed a prospective randomized study in thousands of patients in which the model was used to help improve advance care planning conversations.
I also work on the methods underpinning observational and predictive modeling research. My open source nnet-survival software that allows use of neural networks for survival modeling has been used by researchers internationally. In collaboration with the Stanford Research Informatics Center, I examined how electronic medical record (EMR) survival outcome data compares to gold-standard data from a cancer registry [PubMed ID 35802836]. The EMR data captured less than 50% of deaths, a finding that affects many studies being published that use EMR outcomes data. -
Andrew Gentles
Assistant Professor (Research) of Pathology, of Medicine (BMIR) and, by courtesy, of Biomedical Data Science
Current Research and Scholarly InterestsComputational systems biology of human disease. Particular focus on integration of high-throughput datasets with each other, and with phenotypic information and clinical outcomes.
-
Olivier Gevaert
Associate Professor of Medicine (Biomedical Informatics) and of Biomedical Data Science
Current Research and Scholarly InterestsMy lab focuses on biomedical data fusion: the development of machine learning methods for biomedical decision support using multi-scale biomedical data. We primarily use methods based on regularized linear regression to accomplish this. We primarily focus on applications in oncology and neuroscience.
-
Amato J. Giaccia
Jack, Lulu and Sam Willson Professor, Professor of Radiation Oncology, Emeritus
Current Research and Scholarly InterestsDuring the last five years, we have identified several small molecules that kill VHL deficient renal cancer cells through a synthetic lethal screening approach. Another major interest of my laboratory is in identifying hypoxia-induced genes involved in invasion and metastases. We are also investigating how hypoxia regulates gene expression epigenetically.
-
Iris C. Gibbs, MD, FACR, FASTRO
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsDr. Gibbs is a board-certified radiation oncologist who specializes in the treatment of CNS tumors. Her research focuses on developing new radiation techniques to manage brain and spinal tumors in adults and children. Dr. Gibbs has gained worldwide acclaim for her expertise in Cyberknife robotic radiosurgery.
-
Erin Gibson
Assistant Professor of Psychiatry and Behavioral Sciences (Sleep Medicine)
Current Research and Scholarly InterestsGlia make up more than half of the cells in the human brain, but we are just beginning to understand the complex and multifactorial role glia play in health and disease. Glia are decidedly dynamic in form and function. Understanding the mechanisms underlying this dynamic nature of glia is imperative to developing novel therapeutic strategies for diseases of the nervous system that involve aberrant gliogenesis, especially related to changes in myelination.
-
Harcharan Gill
Kathryn Simmons Stamey Professor, Emeritus
Current Research and Scholarly InterestsBenign Prostatic Hyperplasia- Evaluation and development of new minimally invasive techniques
Endourology: developing, designing and evaluating new instruments
Bladder cancer: outcomes of treatment
BPH: cryotherapy and HIFU -
Jeffrey S. Glenn, M.D., Ph.D.
Joseph D. Grant Professor and Professor of Microbiology and Immunology
Current Research and Scholarly InterestsDr. Glenn's primary interest is in molecular virology, with a strong emphasis on translating this knowledge into novel antiviral therapies. Other interests include exploitation of hepatic stem cells, engineered human liver tissues, liver cancer, and new biodefense antiviral strategies.
-
Gary Glover
Professor of Radiology (Radiological Sciences Lab) and, by courtesy, of Psychology and of Electrical Engineering
Current Research and Scholarly InterestsMy present research is devoted to the advancement of functional magnetic resonance imaging sciences for applications in basic understanding of the brain in health and disease. We collaborate closely with departmental clinicians and with others in the school of medicine, humanities, and the engineering sciences.
-
Jeremy Goldhaber-Fiebert
Professor of Health Policy
BioJeremy Goldhaber-Fiebert, PhD, is a Professor of Health Policy and a Core Faculty Member in the Centers for Health Policy and Primary Care and Outcomes Research. His research focuses on complex policy decisions surrounding the prevention and management of increasingly common, chronic diseases and the life course impact of exposure to their risk factors. In the context of both developing and developed countries including the US, India, China, and South Africa, he has examined chronic conditions including type 2 diabetes and cardiovascular diseases, human papillomavirus and cervical cancer, tuberculosis, and hepatitis C and on risk factors including smoking, physical activity, obesity, malnutrition, and other diseases themselves. He combines simulation modeling methods and cost-effectiveness analyses with econometric approaches and behavioral economic studies to address these issues. Dr. Goldhaber-Fiebert graduated magna cum laude from Harvard College in 1997, with an A.B. in the History and Literature of America. After working as a software engineer and consultant, he conducted a year-long public health research program in Costa Rica with his wife in 2001. Winner of the Lee B. Lusted Prize for Outstanding Student Research from the Society for Medical Decision Making in 2006 and in 2008, he completed his PhD in Health Policy concentrating in Decision Science at Harvard University in 2008. He was elected as a Trustee of the Society for Medical Decision Making in 2011 and Secretary/Treasurer in 2021.
Past and current research topics:
- Type 2 diabetes and cardiovascular risk factors: Randomized and observational studies in Costa Rica examining the impact of community-based lifestyle interventions and the relationship of gender, risk factors, and care utilization.
-Cervical cancer: Model-based cost-effectiveness analyses and costing methods studies that examine policy issues relating to cervical cancer screening and human papillomavirus vaccination in countries including the United States, Brazil, India, Kenya, Peru, South Africa, Tanzania, and Thailand.
- Measles, haemophilus influenzae type b, and other childhood infectious diseases: Longitudinal regression analyses of country-level data from middle and upper income countries that examine the link between vaccination, sustained reductions in mortality, and evidence of herd immunity.
- Patient adherence: Studies in both developing and developed countries of the costs and effectiveness of measures to increase successful adherence. Adherence to cervical cancer screening as well as to disease management programs targeting depression and obesity is examined from both a decision-analytic and a behavioral economics perspective.
- Simulation modeling methods: Research examining model calibration and validation, the appropriate representation of uncertainty in projected outcomes, the use of models to examine plausible counterfactuals at the biological and epidemiological level, and the reflection of population and spatial heterogeneity. -
Steven Goodman
Professor of Epidemiology and Population Health, of Medicine (Primary Care and Population Health) and, by courtesy, of Health Policy
Current Research and Scholarly InterestsI am interested in issues relating to the representation and measurement of evidence in medical research, and determinants of the truth of medical findings, using a Bayesian framework. I also do work in evidence synthesis, comparative effectiveness research, and the ethics of clinical research.
-
Jason Gotlib
Professor of Medicine (Hematology)
Current Research and Scholarly InterestsMy research interests include phase I/II clinical trial evaluation of novel therapies for the following diseases:
--Myelodysplastic syndromes (MDS)
--Chronic myelogenous leukemia (CML)
--Acute myelogenous leukemia (AML)
--Myeloproliferative disorders (MPDs) including:
Hypereosinophilic syndrome
Systemic mastocytosis
BCR-ABL-negative MPDs -
Or Gozani
Dr. Morris Herzstein Professor
Current Research and Scholarly InterestsWe study the molecular mechanisms by which chromatin-signaling networks effect nuclear and epigenetic programs, and how dysregulation of these pathways leads to disease. Our work centers on the biology of lysine methylation, a principal chromatin-regulatory mechanism that directs epigenetic processes. We study how lysine methylation events are generated, sensed, and transduced, and how these chemical marks integrate with other nuclear signaling systems to govern diverse cellular functions.
-
Dita Gratzinger
Professor of Pathology
Current Research and Scholarly InterestsI have research interests in the interaction of hematolymphoid neoplasia with the microenvironment. For example, I use a combination of immunohistochemistry, immunofluorescence and image analysis techniques to evaluate the mesenchymal stromal cell compartment in myelodysplastic syndrome (pre-leukemic bone marrow failure disorder). I also have interests in lymphoma vasculature and the tropism of lymphoma for specific types of vasculature.
-
Edward Graves
Associate Professor of Radiation Oncology (Radiation Physics) and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)
Current Research and Scholarly InterestsApplications of molecular imaging in radiation therapy, development of hypoxia and radiosensitivity imaging techniques, small animal image-guided conformal radiotherapy, image processing and analysis.
-
Nathanael S. Gray
Krishnan-Shah Family Professor
BioNathanael Gray is the Krishnan-Shah Family Professor of Chemical and Systems Biology at Stanford, Co-Director of Cancer Drug Discovery Co-Leader of the Cancer Therapeutics Research Program, Member of Chem-H, and Program Leader for Small Molecule Drug Discovery for the Innovative Medicines Accelerator (IMA). His research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance.
Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. During his six year stay at GNF, Dr. Gray became the director of biological chemistry where he supervised a group of over fifty researchers integrating chemical, biological and pharmacological approaches towards the development of new experimental drugs. Some of the notable accomplishments of Dr. Gray’s team at GNF include: discovery of the first allosteric inhibitors of wild-type and mutant forms of BCR-ABL which resulted in clinical development of ABL001; discovery of the first selective inhibitors of the Anaplastic Lymphoma Kinase (ALK), an achievement that led to the development of now FDA-approved drugs such as ceritinib (LDK378) for the treatment of EML4-ALK expressing non-small cell lung cancer (NSCLC); and discovery that sphingosine-1-phosphate receptor-1 (S1P1) is the pharmacologically relevant target of the immunosuppressant drug Fingomilod (FTY720) followed by the development of Siponimod (BAF312), which is currently used for the treatment of multiple sclerosis.
In 2006, Dr. Gray returned to academia as a faculty member at the Dana Farber Cancer Institute and Harvard Medical School in Boston. There, he has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Dr. Gray’s team developed covalent inhibitors of the T790M mutant of EGFR inspired the development of Osimertinib (AZD9291), now FDA approved for treatment of patients with relapsed lung cancer due to resistance to first generation EGFR inhibitors. Dr. Gray has also developed structure-based, generalized approaches for designing drugs to overcome one of the most common mechanisms of resistance observed against most kinase inhibitor drugs, mutation of the so-called "gatekeeper" residue, which has been observed in resistance to drugs targeting BCR-ABL, c-KIT and PDGFR.
In 2021, Dr. Gray joined Stanford University where he has joined the Stanford Cancer Institute, Chem-H and the Innovative Medicines Accelerator (IMA) to spur the development of prototype drugs.
These contributions have been recognized through numerous awards including the National Science Foundation’s Career award in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011, and the Nancy Lurie Marks endowed professorship in 2015 and the Paul Marks Prize in 2019, and the Hope Funds for Cancer Research in 2023. -
Henry T. (Hank) Greely
Deane F. and Kate Edelman Johnson Professor of Law and, Professor, by courtesy, of Genetics
Current Research and Scholarly InterestsSince 1992 my work has concentrated on ethical, legal, and social issues in the biosciences. I am particularly active on issues arising from neuroscience, human genetics, and stem cell research, with cross-cutting interests in human research protections, human biological enhancement, and the future of human reproduction.
-
Harry B Greenberg
Joseph D. Grant Professor in the School of Medicine, Emeritus
Current Research and Scholarly InterestsMolecular mechanisms of pathogenesis; determinants of protective immunity; host range and tissue tropism in liver and GI tract pathogenic viruses and studies of vaccines in people.
-
Peter Greenberg
Professor of Medicine (Hematology), Emeritus
Current Research and Scholarly InterestsDr Greenberg's clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. These studies are particularly based on his prior laboratory investigations of gene expression and hematopoietic regulation in MDS patients. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the mutation-based prognostic risk system, the IPSS-Molecular (IPSS-M). This project uses such findings to more specifically characterize and treat MDS patients. He is Chair of the NCCN Practice Guidelines Panel for MDS.
-
William Greenleaf
Professor of Genetics
Current Research and Scholarly InterestsOur lab focuses on developing methods to probe both the structure and function of molecules encoded by the genome, as well as the physical compaction and folding of the genome itself. Our efforts are split between building new tools to leverage the power of high-throughput sequencing technologies and cutting-edge optical microscopies, and bringing these technologies to bear against basic biological questions by linking DNA sequence, structure, and function.
